NBIX Form 4 reports multiple insider transactions
ABERNETHY MATT reported multiple insider transaction types in a Form 4 filing for NBIX.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ABERNETHY MATT reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 84,802 shares at a weighted average price of $123.99 per share. Following the reported transactions, holdings were 4,484 shares.
Insider Trade Summary
6,940 shares exercised/converted
Exercise
13 txns
Insider
ABERNETHY MATT
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 2,241 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 2,566 | $0.00 | $0.00 |
| Grant/Award | Stock Option | 44,095 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 7,735 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,241 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,210 | $124.12 | $150K |
| Exercise | Common Stock | 2,566 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,385 | $124.12 | $172K |
| Grant/Award | Common Stock | 9,968 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 5,378 | $124.12 | $668K |
| Exercise | Restricted Stock Unit | 2,133 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,133 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,151 | $123.10 | $142K |
Holdings After Transaction:
Restricted Stock Unit — 21,186 contracts (Direct);
Stock Option — 44,095 contracts (Direct);
Common Stock — 44,881 shares (Direct)
Footnotes (8)
- F1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
- F2. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
- F3. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F4. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,133 shares on February 12, 2026, and will vest as to 2,133 shares on February 12, 2027, 2,134 shares on February 12, 2028, and 2,134 shares on February 12, 2029, subject to the terms and conditions of the award.
- F5. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award.
- F6. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award.
- F7. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F8. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did NBIX CFO Matt Abernethy report on this Form 4?
Matt Abernethy reported RSU and PRSU vesting, a new stock option grant, and related tax-withholding share dispositions. Common shares were acquired via award conversions at no cost, while some shares were withheld by Neurocrine Biosciences to pay taxes due on those vestings.
What new stock option grant did the NBIX CFO receive according to the Form 4?
Matt Abernethy received a stock option covering 44,095 shares of Neurocrine Biosciences common stock at an exercise price of $124.12 per share. The option begins vesting on March 13, 2026, with 1/48th of the shares vesting monthly until fully vested in 2030.
What time-based RSU vesting did the NBIX CFO report for Neurocrine Biosciences?
The filing lists several time-based RSU awards. Portions of grants from February 12, 2025, February 13, 2024, and February 13, 2023 vested in 2026, with remaining tranches scheduled to vest annually through February 2029 or February 2027, depending on the original grant date.
What future vesting schedule applies to the NBIX CFO’s new RSU grant?
The new 7,735 restricted stock units will vest in four equal annual installments. One quarter of the units vest on each of February 13, 2027, 2028, 2029, and 2030, subject to the award’s terms and any continued service or other applicable conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates